ClinicalTrials.gg
Not yet recruitingNCT07734948Updated Jul 29, 2026

Cardiovascular Effects of Purple-Fleshed Potatoes

An interventional study of Purple flesh potato and White flesh potato in PRE-HYPERTENSION, sponsored by Instituto de Investigacion Nutricional, Peru. Not yet recruiting. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Instituto de Investigacion Nutricional, Peru · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Study summary

This study is being done to evaluate the effect on cardiovascular biomarkers and anthocyanin-derived plasma metabolites of Peruvian native purple-fleshed potato consumed over a 4-week period by prehypertensive men ages 18-40 years old. Subjects will undergo blood pressure monitoring, anthropometric measurements, laboratory analysis, plasma metabolic profile assessments and microbiome metagenomic analysis before and after finishing the potato consumption period.

Hypertension is a chronic disease that affects over 20% of Peruvians aged 15+, with higher prevalence in men. Previous studies on purple flesh varieties have shown reductions in blood pressure and improvements in vascular function. Potatoes are a major dietary staple and a source of many compounds beyond carbohydrates, including vitamins, minerals, and polyphenols. Anthocyanins are polyphenol compounds that give purple potatoes their color, and are known for its antioxidant, anti-inflammatory, and vasodilatory properties. Hence, this work aims to generate novel evidence on the cardiovascular benefits of Peruvian purple flesh potatoes that could lead to its inclusion on preventive dietary strategies and enhance the value of local agriculture. Moreover, as purple flesh potatoes have unique anthocyanins such as petunidin and peonidin whose metabolization has not yet been studied, understanding their metabolization and bioavailability will aid in a better understanding of their observed impact on health.

The study is designed as a randomized, controlled, crossover nutritional intervention involving 30 male prehypertensive participants aged 18-40 (BMI \< 30 kg/m2, 120-139 mmHg SBP and/or 80-89 mmHg DBP), with an expected final sample of 21. Each participant will consume a daily portion over a four-week period of potato purée of either purple- or white-fleshed varieties according to the corresponding treatment, with a one-week washout period between treatments. The portion will consist of a rehydrated purée derived from freeze-dried steamed tubers equivalent to 400 grams of fresh weight. All measurements will be taken before each treatment period beginning and after its ending. Anthropometry measurements will include waist circumference, height and weight to calculate BMI. Blood pressure will be measured at fasting and postprandial state. Blood samples will be taken at fasten state for measuring biochemical markers glucose, lipid profile, creatinine, C-reactive protein, and antioxidant capacity. Saliva samples will be taken at fasten state for microbiome analysis. Blood samples for plasma metabolomic analysis will be taken at fasten state before the intervention as a basal measurement and after potato consumption (1 postprandial hour) on the treatment last day. Dietary intake and physical activity will be monitored using 24-hour recall and IPAQ short form questionnaires.

02

Conditions studied

  • PRE-HYPERTENSION

Keywords

  • Purple flesh Potato
  • Pre-hypertension
  • Cardiovascular disease
  • Men
  • Potato
03

In context

Prehypertension

158 studies on the registry are indexed under Prehypertension; 21 are open to participants now.

This study's planned enrollment of 300 is above the median of 66 across 138 interventional studies indexed under Prehypertension.

Browse Prehypertension studies →

Lead sponsor

Instituto de Investigacion Nutricional, Peru is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged 18-40 years.
  • between 18.5 and 35 kg/m².
  • Prehypertensive individuals with systolic blood pressure (SBP) of 120-139 mmHg and/or diastolic blood pressure (DBP) of 80-89 mmHg.
  • Fasting glucose ≤125 mg/dL.
  • Willing to attend the study center for 42 days for potato consumption and measurement procedures.
  • Willing to consume the equivalent of 400 g of fresh potatoes daily during two 4-week periods, separated by a 7-day .
  • Individuals who agree to and sign the form.
  • Not taking blood pressure-lowering and/or cholesterol-lowering medications. Smokers. Taking supplements containing antioxidants. Engaging in high-intensity physical activity according to the short version of the International Physical Activity Questionnaire (IPAQ).

Exclusion criteria

Exclusion Criteria:

  • Individuals with chronic gastrointestinal disorders, kidney disease, or diabetes, previously diagnosed or identified through screening via a questionnaire.
  • Individuals currently taking antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), blood pressure medications, and/or cholesterol-lowering medications.
  • Participants who do not complete the study or who develop an acute health condition during the study period.
  • Participants with C-reactive protein (CRP) levels > 10 mg/L. Smokers.
  • Taking supplements containing antioxidants.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Intervention group

    Other: Purple flesh potato

  • Placebo comparator
    Control group

    Other: White flesh potato

Interventions

  • OtherPurple flesh potato

    Dietary Intervention: Purple flesh potato pureé, rich in anthocyanins food Dietary Intervention: white flesh potato pureé, control

  • OtherWhite flesh potato

    Dietary Intervention: Purple flesh potato puree, rich in anthocyanins food Dietary Intervention: white flesh potato puree, control

06

What researchers measure

Primary outcomes

  1. Changes in blood pressure

    Time frame: 8 weeks (4 weeks per treatment)

Secondary outcomes

  1. Changes in lipid profile

    Time frame: 8 weeks (4 weeks per treatment)

  2. Changes in fasting glucose

    Time frame: 8 weeks (4 weeks per treatment)

  3. Changes in plasma antioxidant capacity

    Time frame: 8 weeks (4 weeks per treatment)

  4. Changes in CRP

    Time frame: 8 weeks (4 weeks per treatment)

Other outcomes

  1. Changes in oral microbiome diversity

    Time frame: 8 weeks (4 weeks per treatment)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Jul 2027, 11 months later.

Of 56 non-industry interventional studies with no phase under Prehypertension, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 37. This study's planned 11 months is below that.

Counting every sponsor, half of 60 studies reached it within 20 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Jul 29, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07734948
Lead sponsor
Instituto de Investigacion Nutricional, Peru
Collaborators
Centro Internacional de la Papa, University of California, Davis
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

Maria R Liria-Dominguez, PhD
Contact
rliria@iin.sld.pe
5113496023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion